4503 Stock News Today | Earnings, Events & Price Alerts

4503 News

EVINOVA FORGES STRATEGIC PARTNERSHIPS WITH ASTELLAS, ASTRAZENECA, AND BRISTOL MYERS SQUIBB TO ENHANCE ITS AI-DRIVEN PLATFORM FOR FASTER GLOBAL CLINICAL DEVELOPMENT

7h agomoomoo

FDA Grants Approval for PADCEV® in Combination with Keytruda® for Specific Bladder Cancer Patients

Nov 21 2025Newsfilter

China Convicts Employee of Japanese Drugmaker of Spying

Jul 16 2025WSJ

Joe Biden’s Prostate Cancer Diagnosis: The Outlook for Advanced Disease

May 19 2025WSJ

Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Feb 10 2025Newsfilter

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership

Dec 31 2024Barron's

Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Partnership

Dec 31 2024Barron's

Sangamo inks $20M gene therapy deal with Astellas; shares rally By Investing.com

Dec 19 2024Investing.com

4503 Events

No data

4503 Monitor News

No data

4503 News & Events

4503 News & Events

4503 News

EVINOVA FORGES STRATEGIC PARTNERSHIPS WITH ASTELLAS, ASTRAZENECA, AND BRISTOL MYERS SQUIBB TO ENHANCE ITS AI-DRIVEN PLATFORM FOR FASTER GLOBAL CLINICAL DEVELOPMENT

FDA Grants Approval for PADCEV® in Combination with Keytruda® for Specific Bladder Cancer Patients

China Convicts Employee of Japanese Drugmaker of Spying

Joe Biden’s Prostate Cancer Diagnosis: The Outlook for Advanced Disease

Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership

Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Partnership

Sangamo inks $20M gene therapy deal with Astellas; shares rally By Investing.com

4503 Events

4503 Monitor News

4503 Earnings Analysis

No Data

People Also Watch

4503 News & Events

4503 News & Events

4503 News

EVINOVA FORGES STRATEGIC PARTNERSHIPS WITH ASTELLAS, ASTRAZENECA, AND BRISTOL MYERS SQUIBB TO ENHANCE ITS AI-DRIVEN PLATFORM FOR FASTER GLOBAL CLINICAL DEVELOPMENT

FDA Grants Approval for PADCEV® in Combination with Keytruda® for Specific Bladder Cancer Patients

China Convicts Employee of Japanese Drugmaker of Spying

Joe Biden’s Prostate Cancer Diagnosis: The Outlook for Advanced Disease

Pfizer and Astellas&#39; PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership

Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Partnership

Sangamo inks $20M gene therapy deal with Astellas; shares rally By Investing.com

4503 Events

4503 Monitor News

4503 Earnings Analysis

No Data

People Also Watch

Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)